Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia (Q34358512)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia |
scientific article |
Statements
1 reference
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia (English)
1 reference
Guido Marcucci
1 reference
John C Byrd
1 reference
Rebecca B Klisovic
1 reference
Michael R Grever
1 reference
William Blum
1 reference
Shujun Liu
1 reference
Lenguyen Huynh
1 reference
Jiuxia Pang
1 reference
Zhiliang Xie
1 reference
Steven Devine
1 reference
Cheryl Kefauver
1 reference
Tamara Vukosavljevic
1 reference
James A Zwiebel
1 reference
Xiaohui Wei
1 reference
Zhongfa Liu
1 reference
Kenneth Chan
1 reference
1 June 2008
1 reference
1 reference
14
1 reference
12
1 reference
3889-3895
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference